Weight loss jabs are now are now available on the NHS for those with a prescription. But a black market for the in-demand ...
Weight-loss drugs have been rolled out by the NHS, but many are buying them through social media and online pharmacies ...
EXPERTS have warned over hundreds rushed to hospital after using weight loss jabs – as half a million Brits now use the ...
A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity ...
The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare ...
Semaglutide, a medication originally designed to treat type 2 diabetes, has recently gained significant attention as a weight ...
The Centers for Medicare and Medicaid Services (CMS) identified 15 drugs it has selected for price negotiations with drug ...
1d
People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.
Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the different forms as a single product.
The phase 3 STEP UP trial enrolled 1407 adults aged 18 years and older with a body mass index of at least 30kg/m2 and without diabetes.
Novo Nordisk says a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight patients reduce their weight by 20 per cent. Kyle Benning has the details and more ...
After Novo Nordisk (NVO) reported results from its Phase 3b STEP UP trial, which showed that adults with obesity achieved a 20.7% weight loss ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback